CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing
16. Dezember 2024 08:00 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
CBIH has formally filed a petition to have Ms. Alexis Bortell serve as a witness in the upcoming DEA hearing on marijuana rescheduling.
A Letter from the Desk of CBIH
09. Dezember 2024 08:00 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings CEO Dante Picazo Addresses Cannabis Reclassification and DEA Hearings
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
06. Dezember 2024 07:30 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
CBIH Unveils the Future of Wellness with Revolutionary Anti-Aging Chip
25. November 2024 08:00 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
our Research and Development team is redefining the possibilities of cannabinoid-based biotechnologies and at the heart of these innovations lies the Rejuv
CORRECTION - Elevai Labs Inc.
14. November 2024 14:35 ET
|
Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
Bone Metabolism Assays Pipeline Research Report 2024 Stages of Development, Region and Countries, Regulatory Path Key Companies, Licensing and Collaboration Details
14. November 2024 09:11 ET
|
Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Bone Metabolism Assays Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update"...
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
22. Oktober 2024 09:54 ET
|
Elevai Labs Inc.
Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
21. Oktober 2024 07:30 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
03. Oktober 2024 15:45 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
03. Oktober 2024 07:30 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,